Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 475 of 520 entries
View as:

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03543969 Org: User:
Start: 06/14/18 End: 12/31/28 Due: 12/31/29

A Phase I/II Study of Sunitinib and Dacarbazine

Phase: N/A Priority: Normal
NCT ID: NCT00496223 Org: User:
Start: 09/30/06 End: 06/30/07 Due: 06/30/08

Facts and Attitudes About Clinical Trials

Phase: N/A Priority: Normal
NCT ID: NCT01269645 Org: User:
Start: 07/31/09 End: 07/31/14 Due: 07/31/15

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

Phase: N/A Priority: Normal
NCT ID: NCT00858403 Org: User:
Start: 03/31/09 End: 07/31/10 Due: 07/31/11

Stress Management Training for Latinas Receiving Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01599520 Org: User:
Start: 03/13/12 End: 11/19/21 Due: 11/19/22

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00005641 Org: User:
Start: 09/30/97 End: 09/30/00 Due: 09/30/01

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

Phase: N/A Priority: Normal
NCT ID: NCT02851056 Org: User:
Start: 09/27/16 End: 08/09/18 Due: 08/09/19

Metformin in Children With Relapsed or Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01528046 Org: User:
Start: 09/24/12 End: 02/03/20 Due: 02/03/21

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Phase: N/A Priority: Normal
NCT ID: NCT03411031 Org: User:
Start: 10/04/18 End: 11/04/21 Due: 11/04/22

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00762255 Org: User:
Start: 09/30/08 End: 07/31/13 Due: 07/31/14

Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00226577 Org: User:
Start: 02/29/04 End: 12/31/08 Due: 12/31/09

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Phase: N/A Priority: Normal
NCT ID: NCT06963346 Org: User:
Start: 04/23/25 End: 04/30/28 Due: 04/30/29

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Phase: N/A Priority: Normal
NCT ID: NCT04798339 Org: User:
Start: 03/30/21 End: 10/31/25 Due: 10/31/26

Promoting a Healthier Lifestyle Among Breast Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT01419613 Org: User:
Start: 08/31/10 End: 05/31/15 Due: 05/31/16

Senior Adult Hepatobiliary Prehab Study

Phase: N/A Priority: Normal
NCT ID: NCT05921552 Org: User:
Start: 06/26/23 End: 04/30/26 Due: 04/30/27

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06660355 Org: User:
Start: 12/23/24 End: 12/31/28 Due: 12/31/29

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03384914 Org: User:
Start: 02/19/18 End: 12/31/27 Due: 12/31/28

Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01455311 Org: User:
Start: 09/30/10 End: 01/31/13 Due: 01/31/14

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03628209 Org: User:
Start: 10/03/19 End: 12/31/25 Due: 12/31/26

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

Phase: N/A Priority: Normal
NCT ID: NCT05677360 Org: User:
Start: 01/09/23 End: 12/31/26 Due: 12/31/27

In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis

Phase: N/A Priority: Normal
NCT ID: NCT01927120 Org: User:
Start: 03/25/14 End: 03/09/17 Due: 03/09/18

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

Phase: N/A Priority: Normal
NCT ID: NCT00609869 Org: User:
Start: 10/31/07 End: 08/31/15 Due: 08/31/16

Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01433172 Org: User:
Start: 03/26/12 End: 02/01/19 Due: 02/01/20

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Phase: N/A Priority: Normal
NCT ID: NCT00624585 Org: User:
Start: 02/29/08 End: 05/31/12 Due: 05/31/13

Comparison of Two Types of Biopsy in Patients With Breast Lesions

Phase: N/A Priority: Normal
NCT ID: NCT00006031 Org: User:
Start: 11/30/99 End: 07/31/06 Due: 07/31/07